Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome (URIC)

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by National Taiwan University Hospital
Sponsor:
Information provided by (Responsible Party):
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT01818505
First received: March 21, 2013
Last updated: April 11, 2014
Last verified: April 2014
  Purpose

Patients with hyperuricemia were confirmed to have higher risks of cardiovascular disease, but the exact mechanism remained to be elucidated. Many connective tissue diseases such as rheumatoid arthritis are often associated with antiphospholipid antibodies-associated endothelial impairment. In the present study, the investigators will analyze the presence of antiphospholipid antibodies in the serum of the patients with gout/asymptomatic hyperuricemia, with a comparison to the patients of osteoarthritis but without hyperuricemia and gout. The investigators expect to find a correlation between these pathogenic antibody and those cardiovascular co-morbidities.


Condition
Antiphospholipid Syndrome
Endothelial Dysfunction
Hyperuricemia
Gout
Metabolic Syndrome

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome

Resource links provided by NLM:


Further study details as provided by National Taiwan University Hospital:

Primary Outcome Measures:
  • development of metabolic syndrome or cardiovascular events [ Time Frame: 36 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Acute myocardial infarct or stroke [ Time Frame: 36 months or more ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

serum


Estimated Enrollment: 210
Study Start Date: March 2013
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts
Gouty arthritis
Patient with gouty arthritis
Asymptomatic hyperuricemia
Patient with asymptomatic hyperuricemia
OA without hyperuricemia
Patient of osteoarthritis but without hyperuricemia and gout

Detailed Description:

Patients with hyperuricemia were confirmed to have higher risks of cardiovascular disease, but the exact mechanism remained to be elucidated. Many connective tissue diseases such as rheumatoid arthritis are often associated with antiphospholipid antibodies-associated endothelial impairment. In the present study, we'll analyze the presence of antiphospholipid antibodies in the serum of the patients with gout/ asymptomatic hyperuricemia, with a comparison to the patients of osteoarthritis but without hyperuricemia and gout. We expect to find a correlation between these pathogenic antibody and those cardiovascular co-morbidities.

Patient eligibility:

  1. Patients with gout
  2. Patients with asymptomatic hyperuricemia
  3. Patients of osteoarthritis but without hyperuricemia and gout Exclusion Criteria: Patients younger than 20 years old
  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

General population

Criteria

Inclusion Criteria:

  1. Patient with gouty arthritis
  2. Patient with asymptomatic hyperurecemia
  3. Patient of osteoarthritis but without hyperuricemia and gout

Exclusion Criteria:

1.Patient younger than 20 y/o.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01818505

Contacts
Contact: Yu-Min Kuo, M.D. 886972655701 543goole@gmail.com

Locations
Taiwan
National Taiwan University Hospital Yun-Lin Branch Recruiting
Dou-Liou City, Yun-Lin County, Taiwan, 640
Contact: Yu-Minn Kuo, MD    8655323911 ext 5826    543goole@gmail.com   
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Principal Investigator: Yu-Min Kuo, MD National Taiwan University Hospital
  More Information

No publications provided

Responsible Party: National Taiwan University Hospital
ClinicalTrials.gov Identifier: NCT01818505     History of Changes
Other Study ID Numbers: URIC
Study First Received: March 21, 2013
Last Updated: April 11, 2014
Health Authority: Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
antiphospholipid syndrome
gouty arthritis
Hyperuricemia
metabolic syndrome
osteoarthritis
cardiovascular co-morbidities

Additional relevant MeSH terms:
Gout
Antiphospholipid Syndrome
Hyperuricemia
Metabolic Syndrome X
Syndrome
Arthritis
Autoimmune Diseases
Disease
Genetic Diseases, Inborn
Glucose Metabolism Disorders
Hyperinsulinism
Immune System Diseases
Insulin Resistance
Joint Diseases
Metabolic Diseases
Metabolism, Inborn Errors
Musculoskeletal Diseases
Pathologic Processes
Purine-Pyrimidine Metabolism, Inborn Errors
Rheumatic Diseases
Antibodies, Antiphospholipid
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on November 27, 2014